Rare Disease AI Diagnostics Investment: Bet on Multiple Solutions Simultaneously, or Close Patient Journey, Evidence, and Clinical Adoption Gaps Before Phased Investment?

Minerva judgment

Recommend closing evidence gaps before phased investment: until three key uncertainties—bottleneck location, data representativeness, and clinical adoption capacity—are resolved, avoid irreversible resource lock-in from simultaneously betting heavily on multiple solutions

Decision owner in the teaching simulationCommittee Chair for Rare Disease Diagnostics Investment, in an independent educational simulation

Human-controlled next action

The committee chair directs the clinical evidence and patient access teams to submit concrete evidence on bottleneck location, data representativeness, and capacity absorption within a set deadline (e.g., one evaluation cycle) before finalizing the decision.

What would reverse the recommendation

If the referral and confirmatory-testing capacity bottleneck shown in F4 remains unresolved, phased investment should pause—even after evidence gaps are closed—to avoid resource misallocation

Illustration of a team reviewing decision cards around a meeting table — **Decision review illustration**
AI-generated illustration, not an actual customer scene or product screenshot. It does not demonstrate outcomes or imply endorsement.

Official public source

Putnam Associates · AI diagnostic opportunity assessment

Evidence and endorsement boundary：Independent teaching simulation. The named consulting firm supplied the public source only; it did not use, review, endorse, sponsor, certify or commission Minerva Advisor. This evidence does not claim customer results, ROI or a permanent service-level guarantee.

Inspect the evidence, then test your own decision context.

See the first-use journey Back to all 50 cases →

MINERVA DECISION READINESS REVIEW

Bring one decision you cannot afford to guess.

Minerva separates evidence, inference and unknowns, then shows options, the strongest objection and what would reverse the recommendation.

Start a Minerva Decision Readiness Review

Bring a real, de-identified decision. Google sign-in and product access are required; your plan and Decision Credits apply. You remain the decision-maker, and no email or external action is sent automatically.